Zimmer Biomet Holdings, Inc.
ZIM.DE News Today: Stay Updated with the Latest Zimmer Biomet Holdings, Inc. News in Real Time
Find ZIM.DE news now at Meyka AI. Stay informed with the latest Zimmer Biomet Holdings, Inc. stocks updates, including price news, market analysis, and expert insights.
FTSE 100 Today, April 08: Oil Tops $110 as Iran Deadline Weighs on Risk
FTSE 100 today: London stocks swing as Brent crude tops $110 and Iran deadline weighs on risk. Energy gains offset pressure on travel, defense, and cyclicals.
Evercore ISI Maintains Outperform on Zillow Group, Inc. Class A (ZG) March 2026
Evercore ISI maintained Outperform on Zillow Group (ZG) March 17, 2026 — ZG analyst rating noted with market reaction and Meyka grade B+
Citigroup Maintains Buy on AMZN (Amazon.com, Inc.) March 17, 2026
Citigroup maintains Buy on AMZN; our AMZN analyst rating coverage reviews price targets and investor implications
Pre-market JPX: 3695.T stock JPY 1663.00: AI services may lift 2026 outlook
Pre-market note on 3695.T stock at JPY 1663.00; Meyka AI forecasts 53.20% 12-month upside
Bank of America, Cowen Maintain FRPT Neutral/Hold March 2026 Freshpet, Inc
FRPT analyst rating maintained March 2026 by BofA and Cowen; implications for Freshpet investors
William Blair and Jefferies Maintain Outperform/Buy on Lantheus (LNTH) March 2026
LNTH analyst rating: William Blair and Jefferies maintain Outperform/Buy on Lantheus in March 2026; Jefferies raises PT to $110
UNH Stock Today April 07: CMS Hikes 2027 MA Rates, Shares Jump
UNH stock jumps after CMS final rate notice lifts 2027 Medicare Advantage rates. We explain what changed, how it supports earnings visibility, and what German investors should watch now.
FECHF stock at USD 3.49 on PNK 07 Apr 2026: watch 50-day trend
FECHF stock update: price USD 3.49 on PNK with low liquidity and Meyka AI forecast USD 1.58
PHO.TO Photon Control (TSX) C$3.60 intraday 07 Apr 2026: oversold bounce setup
PHO.TO stock at C$3.60 intraday on 07 Apr 2026, showing an oversold bounce setup with a C$4.20 12-month target